

# Efficacy and Safety of Cyclosporin A Ophthalmic Emulsion in the Treatment of Moderate-to-severe Dry Eye Disease

## A Dose-Ranging, Randomized Trial

Dara Stevenson, MD,<sup>1</sup> Joseph Tauber, MD,<sup>2</sup> Brenda L. Reis, PhD,<sup>3</sup> The Cyclosporin A Phase 2 Study Group

**Objective:** To investigate the efficacy, safety, formulation tolerability, and optimal dosing of a novel cyclosporin A oil-in-water emulsion formulation for the treatment of moderate-to-severe dry eye disease.

**Design:** Randomized, multicenter, double-masked, parallel-group, dose-response controlled trial.

**Participants:** Total enrollment: 162 patients; cyclosporin A groups: 129 patients; vehicle group: 33 patients.

**Intervention:** Patients instilled study medication (cyclosporin A ophthalmic emulsion 0.05%, 0.1%, 0.2%, or 0.4%, or vehicle) twice daily into both eyes for 12 weeks, followed by a 4-week posttreatment observation period.

**Main Outcome Measures:** Efficacy: rose bengal staining, superficial punctate keratitis, Schirmer tear test, symptoms of ocular discomfort, and the Ocular Surface Disease Index (OSDI; a measure of symptom frequency and impact on vision-related functioning). Safety: biomicroscopy, cyclosporin A blood levels, conjunctival microbiology, intraocular pressure, visual acuity, and monitoring of adverse events.

**Results:** In a subset of 90 patients with moderate-to-severe keratoconjunctivitis sicca, the most significant improvements with cyclosporin A treatment were in rose bengal staining, superficial punctate keratitis, sandy or gritty feeling, dryness, and itching, with improvements persisting into the posttreatment period in some treatment groups. There was also a decrease in OSDI scores, indicating a decrease in the effect of ocular symptoms on patients' daily lives. There was no clear dose-response relationship, but cyclosporin A 0.1% produced the most consistent improvement in objective and subjective end points and cyclosporin A 0.05% gave the most consistent improvement in patient symptoms. The vehicle also performed well, perhaps because of its long residence time on the ocular surface. There were no significant adverse effects, no microbial overgrowth, and no increased risk of ocular infection in any treatment group. The highest cyclosporin A blood concentration detected was 0.16 ng/ml. All treatments were well tolerated by patients.

**Conclusions:** Cyclosporin A ophthalmic emulsions, 0.05%, 0.1%, 0.2%, and 0.4%, were safe and well tolerated, significantly improved the ocular signs and symptoms of moderate-to-severe dry eye disease, and decreased the effect of the disease on vision-related functioning. Cyclosporin A 0.05% and 0.1% were deemed the most appropriate formulations for future clinical studies because no additional benefits were observed with the higher concentrations. *Ophthalmology* 2000;107:967-974 © 2000 by the American Academy of Ophthalmology.

Recent population-based surveys indicate that dry eye disease, or keratoconjunctivitis sicca, affects millions of people worldwide.<sup>1,2</sup> Moreover, as many as 17%<sup>3</sup> to 25%<sup>4</sup> of

patients visiting ophthalmic clinics report dry eye symptoms, making dry eye disease one of the most common complaints seen by ophthalmic specialists. Patients with dry eye disease typically complain of symptoms of ocular discomfort, including a dry, gritty feeling often accompanied by foreign body sensation. Depending on the duration and severity of disease, damage to the ocular surface may also be present. Patients with chronic, uncontrolled dry eye have an increased risk of ocular infections<sup>5,6</sup> and are more likely to have ocular infections that progress to endophthalmitis.<sup>7</sup>

A growing body of evidence suggests that chronic dry eye disease is the result of an underlying cytokine and receptor-mediated inflammatory process that affects the lacrimal gland acini and ducts, leading to abnormalities in the tear film and ultimately disrupting the homeostasis of the ocular surface.<sup>8-11</sup> Most conventional treatments for dry

Originally received: May 4, 1999.

Accepted: January 27, 2000.

Manuscript no. 99216.

<sup>1</sup>Mercy Hospital Professional Building, New Orleans, Louisiana.

<sup>2</sup>Kansas City, Missouri.

<sup>3</sup>Allergan, Inc., Irvine, California.

Reprint requests to Linda Lewis, 575 Anton Boulevard, Suite 900, Costa Mesa, CA 92626.

Preliminary results of this study were presented at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 1997, and at the XIth Congress of the European Society of Ophthalmology, Budapest, Hungary, June 1997.

Supported by a grant from Allergan Inc.

eye disease focus on tear replacement or tear preservation and are incapable of affecting these processes. However, topical treatment with the immunomodulatory agent cyclosporin A has been shown to reduce cell-mediated inflammatory responses associated with inflammatory ocular surface diseases.<sup>12,13</sup> Preliminary studies have demonstrated that treatment with topical cyclosporin A can result in improvement of the signs and symptoms of dry eye disease (Foulks et al, Invest Ophthalmol Vis Sci 1996;37(Suppl):S646; Helms et al, Invest Ophthalmol Vis Sci 1996;37(Suppl):S646).<sup>12,14,15</sup> In addition, several studies have established the efficacy of topical cyclosporin A in the treatment of keratoconjunctivitis sicca in dogs.<sup>16-18</sup> These findings suggest that topical cyclosporin A may provide a unique opportunity to move beyond treatments that only alleviate the symptoms of dry eye disease to therapies that effectively target the inflammatory processes contributing to disease pathogenesis.

The purpose of this study was to investigate the efficacy, safety, patient tolerability, and optimal dosing of a novel cyclosporin A oil-in-water emulsion formulation for the treatment of moderate-to-severe dry eye disease with or without Sjögren's syndrome.

## Methods

### Study Protocol

This report describes a randomized, multicenter, double-masked, parallel-group, dose-response study. The protocol was composed of three phases: a 2-week washout phase, a 12-week treatment phase, and a 4-week posttreatment phase. This study was conducted in compliance with the institutional review board regulations, informed consent regulations, sponsor and investigator obligations, and the Declaration of Helsinki. Written informed consent was obtained from all patients before the initiation of any study medication or study-related procedure.

**Study Population.** Patients were recruited between May 1995 and February 1996 from nine clinical sites throughout the United States. Eligible patients were at least 21 years of age and had a diagnosis of keratoconjunctivitis sicca with or without Sjögren's syndrome refractory to conventional management. Inclusion criteria included Schirmer test (without anesthesia) of 7 mm/5 minutes in at least one eye; mild superficial punctate keratitis defined as a corneal punctate fluorescein staining score of  $\geq 1$  in either eye (scale 0 [none] to 3 [severe]); and one or more moderate ( $\geq +2$ ) dry eye-related symptoms, including itching, burning, blurred vision, foreign body sensation, dryness, photophobia, and soreness or pain. Both eyes were treated, but both eyes were not included in all analyses (see Statistical Methods).

Patients were excluded from study participation if they had any ocular disorder including ocular injury, infection, non-dry eye ocular inflammation, trauma, or surgery within the prior 6 months; were receiving concurrent treatment that could interfere with interpretation of the study results; had any uncontrolled systemic disease or significant illness; or were pregnant, lactating, or considering a pregnancy.

**Study Medications.** The medications used in this study were unit dose vials of unpreserved cyclosporin A 0.05%, 0.1%, 0.2%, and 0.4% ophthalmic emulsion; unit dose vials of unpreserved vehicle for cyclosporin A 0.2% ophthalmic emulsion; and REFRESH lubricant eye drops (Allergan, Irvine, CA). The vehicle for

each concentration of cyclosporin A ophthalmic emulsion is formulated slightly differently because greater oil content is required to dissolve the higher concentrations of the active ingredient. The vehicle for cyclosporin A 0.2% ophthalmic emulsion (hereafter referred to as "vehicle") was chosen for the control because it was near the middle of the range of cyclosporin A concentrations used.

**Study Treatments.** During the washout phase, patients were instructed to discontinue use of all topical ophthalmic medications except for REFRESH. During this time, they were instructed to use REFRESH a minimum of four but no more than eight times daily in each eye. Patients who successfully completed the washout phase were then given their assigned medication (cyclosporin A 0.05%, 0.1%, 0.2%, or 0.4% ophthalmic emulsion or emulsion vehicle) and instructed to instill their medication twice daily (morning and evening) in both eyes for 12 weeks. The use of REFRESH (up to eight times daily in each eye) was allowed during the treatment phase.

**Outcome Measures.** The efficacy measures were rose bengal staining (graded on a scale from 0 = none to 3 = severe); superficial punctate keratitis measured at nasal, temporal, pupil, and inferior and the scores summed (each graded on a scale from 0 = none to 3 = severe); Schirmer tear test (without anesthesia, with nasal stimulation only if needed to determine that the patient had some capacity to secrete tears); symptoms of ocular discomfort (graded by investigator queries on a scale from 0 = none to 4 = very severe, and in patient diaries on a scale from 0 = no discomfort to 4 = discomfort that interferes with normal daily activity); tear film debris (graded on a scale of 0 = none to 4 = very severe); tear breakup time; and the frequency and amount of REFRESH used.

In addition, patient response to treatment was evaluated using the Ocular Surface Disease Index (OSDI), a global assessment parameter consisting of 12 questions designed to assess the symptoms of ocular irritation consistent with dry eye disease and their impact on vision-related functioning. The questions covered three areas: ocular symptoms, environmental triggers, and vision-related function. Each question was phrased in terms of frequency (how often they were aware of a symptom, how often they experienced difficulty with a specific task because of their symptoms, etc) and graded on a scale from 0 to 4 (where 0 = "never" and 4 = "all the time"). Patient responses to all answers were then combined for a composite OSDI score ranging from 0 to 100.

Treatment safety was assessed by biomicroscopy, measurement of cyclosporin A blood levels, conjunctival microbiology, hematology and blood chemistry panels, intraocular pressure by applanation tonometry, and visual acuity by a 96% contrast Regan Letter Acuity Chart. Throughout the study, patients were monitored for signs and symptoms of adverse events and formulation tolerability. Any reported adverse event was graded by the investigator for severity (mild, moderate, or severe) and assessed for relationship to the study treatment (none, unlikely, possible, probable, definite, or unknown).

Patients were evaluated at weeks 4, 8, and 12 during the treatment phase. During these visits patients were evaluated for changes from baseline in Schirmer tear test, rose bengal staining, superficial punctate keratitis scores, symptoms of ocular discomfort, biomicroscopy, and visual acuity. After the completion of the treatment phase, patients were also evaluated at posttreatment weeks 2 and 4. During both visits patients were assessed for Schirmer tear test, rose bengal staining, superficial punctate keratitis, ocular symptoms of discomfort, biomicroscopy, and visual acuity.

Whole blood was obtained from all patients for evaluation of cyclosporin A trough levels at baseline; treatment weeks 1, 4, and 12; and posttreatment week 4. At week 12, additional blood samples were drawn at one study site only for evaluation of peak cyclosporin A concentrations. For evaluation of trough levels,

blood was drawn immediately before the morning dose of study medication. For evaluation of peak levels, blood was drawn 1, 2, and 4 hours after instillation of the final dose of study medication at week 12.

Blood samples were sent to the Allergan Pharmacokinetics Laboratory, where they were assayed by liquid chromatography-mass spectroscopy/mass spectroscopy (LC-MS/MS) with a detection limit of 0.1 ng/ml. One milliliter of human blood was acidified with 2 ml of 0.1 N HCl solution and analytes extracted with 5 ml of methyl *t*-butyl ether. After separation from the acidified aqueous layer, the organic layer was made basic with 2 ml of 0.1 N NaOH, centrifuged, and the organic extract was then evaporated. The dried extract was reconstituted in 200  $\mu$ l of mobile phase A and B (1:1 v/v) and 100  $\mu$ l was injected into the LC-MS/MS system. The LC-MS/MS analysis was conducted on a PE-Sciex API III<sup>+</sup> triple quadrupole mass spectrometer (Perkin Elmer, Norwalk, CT) coupled to a Shimadzu HPLC system (Columbia, MD). Chromatography was performed on a Keystone BDS Hypersil C8 column (50  $\times$  2 mm, 3  $\mu$ m) with a binary mixture of 2 ammonium acetate/0.4% formic acid in water (mobile phase A) and 2 mmol/l ammonium acetate/0.4% formic acid in acetonitrile (mobile phase B) under gradient elution. The HPLC effluent flow rate of 300  $\mu$ l/min was split, with 75  $\mu$ l/min directed to the atmospheric ionization source. The mobile phase was 60% B at 0 to 0.5 minute, increased linearly to 95% B at 1 minute, held at 95% B from 1 to 2.5 minutes, and then decreased to 60% B at 3 minutes (held 1 minute). Cyclosporin G was used as the internal standard.

The PE-Sciex MacQuan software (PE-Sciex Instruments, Concord, Ontario, Canada) was used to determine peak areas of analyte and internal standard, peak area ratios of analyte/internal standard, calibration curves, and calculated concentrations of unknowns. The accuracy and precision of the LC-MS/MS method was assessed within each run using quality control blood samples at 0.1, 0.2, 1, and 5 ng/ml. The intraday accuracy (percent ratio of observed to nominal concentration) ranged from 100% to 109%, with precision (coefficient of variation) ranging from 3% to 10%. The interday accuracy ranged from 102% to 113%, with precision ranging between 1% and 13%.

At four selected study centers, ocular samples for microbiologic evaluation were collected from the conjunctival cul de sac at baseline, treatment week 12, and posttreatment week 4 and sent to a centralized laboratory for culture and organism identification.

**Statistical Methods.** Efficacy variables from subjective measurements with data collected on both eyes were analyzed by averaging the data from both eyes. Efficacy variables from objective measurements with data collected on both eyes were analyzed using data from the worse eye. The worse eye was defined as the eye with the worse Schirmer value and the worse superficial punctate keratitis value (pupil and nasal areas only) at baseline.

Because of the heterogeneity of patient disease profiles, subgroup analyses of patients who had various degrees of disease severity were analyzed separately. Only patients with moderate-to-severe dry eye disease at baseline were included in the efficacy analysis described in this report. All patients who received study medication were included in the analysis of safety variables.

Demographic parameters were summarized with descriptive statistics and frequency tables. Efficacy parameter comparisons among treatment groups were analyzed with the Kruskal-Wallis test. Pairwise comparisons between treatment groups were analyzed with the Wilcoxon rank sum test. Within-group changes from baseline were evaluated with the Wilcoxon signed-rank test. REFRESH use, intraocular pressure, and laboratory variables were analyzed by analysis of variance. Within-group changes from baseline were evaluated with the paired *t* test. Adverse event data were summarized by frequency tables. A two-sided test with *P* = 0.05 was considered statistically significant for all main effects.

The null hypothesis was that there were no differences among the treatment groups with regard to changes from baseline values. The alternative hypothesis was that there was a change.

Power was calculated to detect an among-group difference in change from baseline in categorized Schirmer tear values at week 12. For a sample size of 12 to 15 patients in the moderate-to-severe subgroup analysis, a standard error of 0.394 and standard deviation of 0.881, the power to detect a one grade difference was 0.69.

## Patient Treatment Assignment

Qualified patients within each investigator's population were assigned equally to one of the five masked treatment groups sequentially, corresponding to a randomization schedule generated by the sponsor and using a block of five design.

## Study Masking

All study medications were liquids of similar appearance, dispensed in identical unit dose vials, sealed in identical two-compartment plastic pouches, and packed in identical boxes of 16 pouches each. Each pouch and packing box was coded with a shipment number and the patient number.

When each box was dispensed, the tear-off portion of the label was attached to the patient's case report form. If necessary (because of a serious or severe adverse event), the investigator could irreversibly unmask the tear-off portion of the patient's medication label to determine which study medication the patient had received to institute appropriate patient care.

## Results

Because this was the first clinical trial conducted with this new cyclosporin A formulation, it was designed to function as a pilot study for future investigations. Therefore, patients who varied widely in the severity of their dry eye were enrolled. The data from all patients who received study medication (intent-to-treat population) were analyzed. However, a subgroup analysis revealed a sizable population of patients who had moderate-to-severe dry eye disease at baseline. Moderate-to-severe dry eye disease was defined as a Schirmer tear test 5 mm/5 minutes at baseline in at least one eye and superficial punctate keratitis (pupil and nasal average) of 1.5 averaged over both eyes. Because these patients represent the greatest therapeutic challenge for any dry eye treatment, the efficacy analysis presented here is confined to the evaluation of this moderate-to-severe subgroup. This subgroup also represents the most appropriate target population for future clinical studies of dry eye therapeutics because these patients have sufficient manifestations of the disease to allow the response to therapeutic intervention to be more objectively evaluated. Data from all patients were included in the safety analysis.

## Participant Flow and Follow-up

A total of 162 patients was enrolled: 129 in the cyclosporin A groups and 33 in the vehicle group (Table 1). Eight patients were discontinued for administrative reasons. Of the four patients discontinued because of adverse events, two were in the vehicle group (one with a visual disturbance and ocular burning, and one with conjunctivitis and a contact irritation dermatitis), one was in the cyclosporin A 0.2% group (ocular burning) and one was in the cyclosporin A 0.4% group (myocardial infarction). Only the ocular adverse events were considered to be possibly or probably related to the study medication.

Table 1. Patient Disposition

Treatment Group	Moderate-to-Severe Dry Eye Disease (n = 90)				Intent-to-Treat Population (Total Enrollment) (n = 162)			
	Completed		Discontinued		Completed		Discontinued	
	n	%	n	%	n	%	n	%
Vehicle	16	100.0	0	0.0	30	90.9	3	9.1
CsA 0.05%	17	100.0	0	0.0	30	96.8	1	3.2
CsA 0.1%	18	94.7	1	5.3	30	93.8	2	6.3
CsA 0.2%	20	100.0	0	0.0	32	94.1	2	5.9
CsA 0.4%	17	94.4	1	5.6	28	87.5	4	12.5
Total	88	97.8	2	2.2	150	92.6	12	7.4

CsA = cyclosporin A.

Of the 90 patients with moderate-to-severe dry eye disease, 16 were in the vehicle group, 17 in the cyclosporin A 0.05% group, 19 in the cyclosporin A 0.1% group, 20 in the cyclosporin A 0.2% group, and 18 in the cyclosporin A 0.4% group. One patient in the cyclosporin A 0.1% group was discontinued for personal reasons, and one patient in the cyclosporin A 0.4% group was discontinued because of a myocardial infarction (same patient as mentioned earlier). No patients' medications were unmasked during this study.

**Patient Demographics**

The demographic characteristics of the patient population are listed in Table 2. Note that the mean patient age was approximately 58 years, that more than 80% of patients were women, and that approximately 90% were white. Approximately 32% of the patients in the moderate-to-severe dry eye group were also Sjögren's syndrome patients. Sjögren's syndrome was defined as the presence of one or more of the following in the blood: antinuclear antibodies (>0 titer); rheumatoid factor (30 international units/ml); Sjögren's syndrome A (>10 IU/ml) or B (>5 IU/ml) antibodies. No significant differences were noted among the treatment groups for either the intent-to-treat or moderate-to-severe dry eye populations.

**Efficacy Analysis**

At baseline, mean scores for conjunctival rose bengal staining ranged from 1.2 to 2.0 for both temporal and nasal regions in all

treatment groups. Significant improvements from baseline in temporal conjunctival rose bengal staining scores were observed with cyclosporin A 0.1% at all treatment and posttreatment visits ( $P \leq 0.016$ ), with cyclosporin A 0.2% at week 12 and both posttreatment visits ( $P \leq 0.047$ ), with cyclosporin A 0.4% at week 8 ( $P = 0.031$ ), and with the emulsion vehicle at week 12 ( $P = 0.047$ ) (Fig 1). Cyclosporin A 0.1% produced significantly greater improvements in temporal conjunctival rose bengal staining scores than vehicle ( $P = 0.006$ ), cyclosporin A 0.05% ( $P = 0.022$ ), and cyclosporin A 0.4% ( $P = 0.007$ ) at posttreatment week 2.


Significant improvements from baseline in nasal conjunctival rose bengal staining scores were observed with cyclosporin A 0.2% at all treatment and posttreatment visits ( $P \leq 0.022$ ), with cyclosporin A 0.1% and 0.05% at treatment week 4 through posttreatment week 2 ( $P \leq 0.031$ ), in the cyclosporin A 0.4% group at posttreatment week 2 ( $P = 0.031$ ), and in the vehicle group at treatment weeks 8 and 12 ( $P \leq 0.025$ ). There were no significant among-group differences in the change from baseline in nasal conjunctival rose bengal staining.

At baseline, mean scores for superficial punctate keratitis ranged from 1.6 to 1.9 in all treatment groups. Cyclosporin A 0.1% produced the greatest improvement from baseline in superficial punctate keratitis scores throughout the treatment and posttreatment periods (range, -0.9 to -1.4 units) (Fig 2). With the exception of the 0.05% concentration at treatment week 12 and posttreatment week 4, significant improvements from baseline in superficial punctate keratitis were seen in all cyclosporin A treat-


Table 2. Patient Demographics

	Moderate-to-Severe Dry Eye Disease (n = 90)	Intent-to-Treat Population (n = 162)
Age		
Mean (range)	58 (31-88)	59 (31-88)
Gender (%)		
Male	17 (18.9)	26 (16.0)
Female	73 (81.1)	136 (84.0)
Race (%)		
White	82 (91.1)	145 (89.5)
Black	4 (4.4)	12 (7.4)
Asian	0 (0.0)	1 (0.6)
Hispanic	4 (4.4)	4 (2.5)
Sjögren's syndrome (%)	29 (32.2)	43 (26.5)

CsA = cyclosporin A; NA = data not available.



**Figure 1.** Change from baseline in temporal rose bengal staining. CsA, Cyclosporin A. \*, Significantly different from baseline ( $P \leq 0.047$ ); †, Significantly different from vehicle, cyclosporin A 0.05%, and cyclosporin A 0.4% ( $P \leq 0.022$ ).



**Figure 2.** Change from baseline in superficial punctate keratitis. CsA, Cyclosporin A. \*, Significantly different from baseline ( $P \leq 0.018$ ).


ment groups at all time points during the 12-week treatment phase ( $P \leq 0.012$ ) and 4-week posttreatment period ( $P \leq 0.018$ ). Significant improvement in superficial punctate keratitis was also observed in patients treated with vehicle at treatment weeks 8 and 12 and posttreatment week 2 ( $P \leq 0.041$ ). No statistically significant among-group differences in superficial punctate keratitis values were observed.

Baseline values for Schirmer tear test wetting scores ranged from 2.4 to 3.1 in all treatment groups. The most consistent improvements were in the cyclosporin A 0.1% group, with mean increases in wetting length of 4.3 mm at week 8 and 2.8 mm at week 12, but these increases only approached statistical significance (week 8,  $P = 0.051$ ; week 12,  $P = 0.055$ ). The only statistically significant improvement from baseline occurred in the cyclosporin A 0.4% group at treatment week 4 ( $P = 0.008$ ) and posttreatment week 4 ( $P = 0.023$ ), whereas a significant worsening occurred in the vehicle group at week 4 (3.0 mm,  $P = 0.047$ ). Cyclosporin A 0.4% produced significantly ( $P \leq 0.025$ ) greater improvements from baseline in Schirmer tear test results than either vehicle or cyclosporin A 0.2% at posttreatment week 4.

Symptoms of ocular discomfort were evaluated from scheduled visit queries from the clinical investigator and from self-administered, weekly patient diaries. Baseline symptom results suggest that patients may have consistently underreported the severity of their symptoms when responding to the query from the health professional compared with what they recorded in their diaries. Therefore, only symptom data from patient diaries (using the entries immediately before each scheduled visit) are presented.

At baseline, the mean score for sandy or gritty feeling ranged from 1.7 to 2.2 (mild to moderate) in all treatment groups. There was a significant improvement from baseline in sandy or gritty feeling in the cyclosporin A 0.05% and 0.4% groups at several visits ( $P \leq 0.039$ ) (Fig 3). At treatment week 12, all cyclosporin A treatment groups had significantly greater improvements in sandy or gritty feeling than the vehicle group ( $P \leq 0.04$ ). This significant difference from vehicle was also seen at posttreatment week 2 in the cyclosporin A 0.05% and 0.4% groups ( $P \leq 0.006$ ) and at posttreatment week 4 in the cyclosporin A 0.05%, 0.2%, and 0.4% groups ( $P \leq 0.027$ ). At posttreatment week 2, the cyclosporin A 0.4% and 0.05% groups also demonstrated a significantly greater improvement than the cyclosporin A 0.2% group ( $P \leq 0.037$ ).

At baseline, the mean score for ocular dryness ranged from 2.3 to 2.7 (moderate to severe) in all treatment groups. Significant improvements from baseline in ocular dryness were seen at two or more time points in all cyclosporin A groups except the cyclosporin A 0.1% group ( $P \leq 0.036$ ) (Fig 4). At posttreatment week




**Figure 3.** Change from baseline in sandy or gritty feeling. CsA, Cyclosporin A. \*, Significantly different from baseline ( $P \leq 0.039$ ); †, significantly different from vehicle ( $P \leq 0.027$ ); §, significantly different from cyclosporin A 0.2% ( $P \leq 0.037$ ).

4, cyclosporin A 0.05%, 0.2%, and 0.4% groups all demonstrated significantly greater improvements in ocular dryness than did the vehicle group ( $P \leq 0.010$ ).

At baseline, the mean score for ocular itching ranged from 1.4 to 1.9 (mild to moderate) in all treatment groups. Significant improvements from baseline in ocular itching were seen at one or more time points in all of the cyclosporin A groups ( $P \leq 0.031$ ) but not in the vehicle group. The magnitude of improvement in the cyclosporin A groups was larger than that in the vehicle group at all time points, but there were no statistically significant differences among any of the groups at any time point.

There were no significant within-group or between-group differences in photophobia, pain, or burning and stinging at any time point. The mean scores at baseline for all these parameters ranged from 1 to 2 (mild to moderate) in all treatment groups.

Baseline OSDI scores ranged from 33 to 42 (on a scale from 0 to 100, where 0 indicates no disability and 100 indicates complete disability) in all treatment groups. At both treatment week 12 and posttreatment week 4, there was at least a trend toward improvement in the OSDI score in the cyclosporin A 0.1%, 0.2%, and 0.4% groups, whereas there was either no change or worsening in the vehicle group (Fig 5). At week 12, cyclosporin A 0.1% and 0.2% significantly reduced OSDI scores ( $P \leq 0.008$ ). This decrease was significantly greater with cyclosporin A 0.1% than with cyclosporin A 0.05% or 0.2% ( $P \leq 0.032$ ). This improvement in OSDI scores persisted into the posttreatment period, with a significant



**Figure 4.** Change from baseline in ocular dryness. CsA, Cyclosporin A. \*, Significantly different from baseline ( $P \leq 0.036$ ); †, significantly different from vehicle ( $P \leq 0.010$ ).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.